Abstract
Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 635-642 |
| Number of pages | 8 |
| Journal | Journal of Perinatology |
| Volume | 30 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2010 |
Fingerprint
Keywords
- IVIg
- immune function
- neonate
- premature
- sepsis
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Obstetrics and Gynecology
Cite this
}
Does IVIg administration yield improved immune function in very premature neonates. / Wynn, J. L.; Seed, P. C.; Cotten, C. M.
In: Journal of Perinatology, Vol. 30, No. 10, 01.10.2010, p. 635-642.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Does IVIg administration yield improved immune function in very premature neonates
AU - Wynn, J. L.
AU - Seed, P. C.
AU - Cotten, C. M.
PY - 2010/10/1
Y1 - 2010/10/1
N2 - Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.
AB - Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.
KW - IVIg
KW - immune function
KW - neonate
KW - premature
KW - sepsis
UR - http://www.scopus.com/inward/record.url?scp=77957585989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957585989&partnerID=8YFLogxK
U2 - 10.1038/jp.2009.197
DO - 10.1038/jp.2009.197
M3 - Review article
C2 - 20054335
AN - SCOPUS:77957585989
VL - 30
SP - 635
EP - 642
JO - Journal of Perinatology
JF - Journal of Perinatology
SN - 0743-8346
IS - 10
ER -